Natera NTRA Jumps As NCCN Endorsement Fuels Bullish Targets

Natera Inc. jumps as pivotal clinical trial success boosts confidence in its genetic testing pipeline; stocks have been trading up by 10.74 percent

Live Update At 16:02:22 EDT: On Wednesday, June 24, 2026 Natera Inc. stock [NASDAQ: NTRA] is trending up by 10.74%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

NTRA has been grinding higher on heavy interest, and the tape shows it. Over the last couple of weeks, Natera climbed from the low $210s to close near $260, a strong momentum leg that confirms buyers are in control. The most recent daily bar shows an open around $243 and a push to $264.65 before closing at $259.97, signaling aggressive dip buying throughout the session.

Intraday, NTRA traded in a steady uptrend, with a clear staircase pattern from the mid‑$240s at the open to the high‑$260s into the close. That kind of orderly grind, with higher lows and controlled pullbacks, is exactly what momentum traders like to see when they’re stalking continuation.

Under the hood, Natera is still unprofitable, with an EBIT margin around -13.1% and negative returns on equity and assets. But revenue tells a different story. Sales run near $2.31B annually, growing over 40% on multi‑year trends, and the oncology franchise is already generating more than $1B in annualized revenue. A 65.1% gross margin gives NTRA room to eventually leverage fixed costs if volume continues to ramp.

More Breaking News

• DFTX Stock Soars After Phase 3 Depression Trial Win
• EHGO Stock Rockets On Volatility As Traders Pile In
• FRTT Stock Slides After Volatile Spike Draws Momentum Traders
• SFM Stock Balances Kroger Threat With Coffee Expansion

On the balance sheet, the current ratio near 3 and modest debt levels mean liquidity risk looks contained. For traders, that mix—fast growth, solid balance sheet, but no earnings yet—screams “high‑beta story stock” where sentiment and catalysts drive the next leg.

Why Traders Are Watching NTRA Right Now

NTRA is front and center on trading screens because the core oncology product, Signatera, just got a huge credibility boost. The National Comprehensive Cancer Network updated its bladder cancer guidelines to add ctDNA‑MRD testing using an FDA‑approved, tumor‑informed PCR‑NGS assay. In practice, that effectively puts Natera’s Signatera at Category 1 status—the highest level of evidence—for guiding adjuvant immunotherapy in muscle‑invasive bladder cancer.

For traders, guideline inclusion is not just another press release. When NCCN names Signatera and gives it Category 1 support, it bakes Natera into standard clinical workflows. That typically translates into more orders per patient, more oncologists leaning on the test, and a longer revenue tail. This is especially true here, where Signatera guides adjuvant atezolizumab use in MRD‑positive patients within a year of cystectomy—a high‑stakes decision point in bladder cancer care.

Wall Street is taking notice. BTIG bumped its Natera price target from $250 to $270 and reiterated a Buy after the NCCN change, signaling that models are being recalibrated to higher volume assumptions. Leerink also highlighted that Natera’s Signatera is uniquely named in the guidelines and called this a key catalyst for community oncology adoption, not just at elite centers. That’s where the real scale sits.

RBC Capital Markets added fuel by resuming coverage of NTRA with an Outperform rating and a $275 target. They point to Natera’s greater than 90% share in the high‑value oncology MRD testing market, plus Signatera growth north of 70% year over year and more than $1B in annualized revenue. In short, this is no longer a small speculative story—Natera has a dominant MRD franchise with heavyweight backing.

Interestingly, despite the Category 1 news, NTRA traded down more than 2% in premarket action around the announcement, likely a classic “sell the news” reaction after a big run. For active traders, that kind of shakeout in the face of strong fundamentals often sets up the next trend move once weak hands are flushed.

Beyond oncology, Natera is also building a second growth pillar in transplant. The company plans 21 studies—seven of them oral presentations—at the American Transplant Congress, spotlighting its Prospera donor‑derived cell‑free DNA test. Data from PEDAL and ProActive show Prospera can flag adverse outcomes even when biopsies look clean and that consistently low dd‑cfDNA levels line up with far lower rejection and graft loss. That kind of clinical evidence can support broader reimbursement and routine use, giving NTRA another engine for future revenue.

Conclusion

NTRA is trading like a classic catalyst‑driven momentum name: strong uptrend on the chart, powerful fundamental tailwinds underneath. The latest NCCN Category 1 recommendation for Signatera in muscle‑invasive bladder cancer, layered on top of recent FDA companion diagnostic approval, locks Natera deeper into standard‑of‑care algorithms. For traders, that’s the kind of structural shift that can support multi‑year revenue ramps, not just a one‑day headline spike.

Analyst targets in the $270–$275 range from BTIG and RBC show how the Street is leaning. They see Natera’s MRD dominance, >90% share, and more than $1B in Signatera annualized revenue as proof that this is already a scaled platform. Add rapid top‑line growth, rich gross margins, and expanding transplant data from Prospera, and NTRA screens like a high‑growth diagnostics leader, even if the bottom line is still red.

The key for traders is to respect both the upside and the risk. Unprofitable, high‑multiple names like Natera can move sharply in both directions on any surprise—good or bad. Tight risk management matters here. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. That mindset pairs well with classic momentum‑style trading. As Tim Sykes loves to remind traders, “Cut losses quickly, singles add up, and only stay in a play as long as the risk and reward still make sense.” For NTRA, the story and momentum are currently aligned, but the chart will always have the final say.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.